1. Volume 71, Issue 5, Pages 710-713 (May 2017)
Predicting Competing Mortality in Patients Undergoing Radical Prostatectomy Aged 70 yr or Older 
Michael Froehner, Rainer Koch, Matthias Hübler, Stefan Zastrow, Manfred P. Wirth 
European Urology 
Volume 71, Issue 5, Pages (May 2017)
DOI: /j.eururo
Copyright © 2016 European Association of Urology Terms and Conditions

2. Fig. 1
Cumulative competing mortality curves with Pepe Mori test p values and Akaike's information criterion (lower is better) for the suggested mortality score (upper diagram in the left column) and five other comorbidity scores using the stratification 0 versus 1 versus 2 versus 3 or more points for all scores in our sample of 543 patients who underwent radical prostatectomy at an age of 70 yr or older. The Akaike's information criterion was 1425 for the current score and ranged between 1452 (unweighted Charlson score) and 1460 (modified Lee mortality index) for the comparators. The following modifications were made with the tested scores according to the availability of data in our database: (1) modified Charlson score [6]: data on depression, Parkinson disease, and multiple sclerosis was not available in our database, these conditions were not considered in calculating this modified Charlson score, (2) Lee mortality index [7]: no subdivision between skin cancer and nonskin cancer was made; functional impairments which were not available in our database and are unlikely of being encountered in candidates for radical prostatectomy were ignored; patients with unknown smoking status were considered nonsmokers, (3) prostate cancer specific comorbidity index [8]: other neurological disease, mild renal disease, arrhythmia, valve disease, and inflammatory bowel disease were not available in our database and were not considered in calculating the index. All cases of chronic lung disease were considered mild in our study. No subdivision between obstructive and restrictive lung disease was made. Age-related components in the Lee mortality index [7] and the prostate cancer specific comorbidity index [8] were not used in calculating these scores for comparison.
European Urology  , DOI: ( /j.eururo )
Copyright © 2016 European Association of Urology Terms and Conditions